CRST and Kancera AB signed a contract for a First-in-human trial with KAND145
CRST and Kancera AB entered into a contract for a First-in-human trial of KAND145, Kancera’s second generation fractalkine blocking drug candidate, primarily intended for cancer indications.
Kancera AB, a Swedish biotech company, is focusing on developing small molecule drugs targeting the fractalkine system for treatment of severe inflammatory diseases and cancer with high medical need. “We are glad to work with CRST again and will utilize their strong expertise in First-in-human trial design and conduct. This trial is strategically very important for Kancera and we have very good experience from working with CRST on previous trials,” says Peter Selin, Executive Vice President Corporate Development and Finance of Kancera AB.
“I am glad that Kancera wanted to continue the good collaboration with CRST in this new and important project. ,” says Antti Iitiä, Chief Executive Officer of CRST.
CRST and Kancera AB entered into a contract for a First-in-human trial of KAND145, Kancera’s second generation fractalkine blocking drug candidate, primarily intended for cancer indications.
Kancera AB, a Swedish biotech company, is focusing on developing small molecule drugs targeting the fractalkine system for treatment of severe inflammatory diseases and cancer with high medical need.
“We are glad to work with CRST again and will utilize their strong expertise in First-in-human trial design and conduct. This trial is strategically very important for Kancera and we have very good experience from working with CRST on previous trials,” says Peter Selin, Executive Vice President Corporate Development and Finance of Kancera AB.
“I am glad that Kancera wanted to continue the good collaboration with CRST in this new and important project. ,” says Antti Iitiä, Chief Executive Officer of CRST.